Table 1 Base case and sensitivity analysis by geographic area (SA includes only studies with birth prevalence measure) (detection rate per 100,000 newborns)
| Base case | Sensitivity analysis (birth prevalence) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MMA | Isolated MMA | MMA | Isolated MMA | |||||||||
| Region |
point estimate (95% CI) | Number of studies | I2 | point estimate (95% CI) | Number of studies | I2 |
point estimate (95% CI) | Number of studies | I2 |
point estimate (95% CI) | Number of studies | I2 |
| North America |
1.22 (0.61–2.01) | 10 | 79.79% |
0.38 (0.09–0.79) | 8 | 53.23% |
1.36 (0.71–2.20) | 9 | 76.46% |
0.42 (0.09–0.91) | 7 | 53.07% |
| Europe |
1.12 (0.50–1.91) | 11 | 79.22% |
0.60 (0.16–1.23) | 6 | 2.17% |
1.55 (0.51–3.02) | 9 | 79.95% |
0.60 (0.16–1.23) | 6 | 2.17% |
| Asia-Pacific |
0.79 (0.44–1.21) |
12 (15 cohorts) | 45.46% |
0.51 (0.32–0.74) |
9 (12 cohorts) | 0.00% |
1.00 (0.46–1.69) | 11 | 44.76% |
0.57 (0.27–0.96) | 8 | 0.00% |
| MENA |
6.04 (4.02–8.41) | 6 | 15.78% |
5.69 (2.54–9.87) | 2 | NA |
5.60 (2.94–8.94) | 5 | 21.45% | NA | NA | NA |